Stryker Co. (NYSE:SYK) Shares Bought by Harvest Portfolios Group Inc.

Harvest Portfolios Group Inc. boosted its holdings in Stryker Co. (NYSE:SYK - Free Report) by 10.6% during the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 168,984 shares of the medical technology company's stock after purchasing an additional 16,194 shares during the quarter. Stryker comprises 2.0% of Harvest Portfolios Group Inc.'s portfolio, making the stock its 9th largest position. Harvest Portfolios Group Inc.'s holdings in Stryker were worth $61,047,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in SYK. Centennial Bank AR increased its stake in shares of Stryker by 106.7% in the 2nd quarter. Centennial Bank AR now owns 93 shares of the medical technology company's stock worth $32,000 after purchasing an additional 48 shares in the last quarter. Central Pacific Bank Trust Division purchased a new stake in shares of Stryker in the first quarter worth about $39,000. HBW Advisory Services LLC bought a new position in shares of Stryker during the 3rd quarter valued at approximately $42,000. Grove Bank & Trust lifted its position in Stryker by 84.8% during the third quarter. Grove Bank & Trust now owns 122 shares of the medical technology company's stock valued at $44,000 after purchasing an additional 56 shares during the last quarter. Finally, DT Investment Partners LLC grew its position in Stryker by 114.3% in the third quarter. DT Investment Partners LLC now owns 135 shares of the medical technology company's stock worth $49,000 after acquiring an additional 72 shares in the last quarter. Institutional investors own 77.09% of the company's stock.

Stryker Stock Down 0.2 %

Shares of SYK traded down $0.84 during midday trading on Wednesday, hitting $369.02. The company had a trading volume of 1,366,185 shares, compared to its average volume of 1,257,470. The company has a quick ratio of 1.22, a current ratio of 1.91 and a debt-to-equity ratio of 0.66. The company's 50 day moving average price is $360.66 and its 200 day moving average price is $344.95. Stryker Co. has a 52 week low of $266.93 and a 52 week high of $376.04. The stock has a market cap of $140.68 billion, a price-to-earnings ratio of 39.55, a PEG ratio of 2.77 and a beta of 0.91.

Stryker (NYSE:SYK - Get Free Report) last announced its quarterly earnings results on Tuesday, October 29th. The medical technology company reported $2.87 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.77 by $0.10. The company had revenue of $5.49 billion during the quarter, compared to the consensus estimate of $5.37 billion. Stryker had a net margin of 16.34% and a return on equity of 23.07%. The company's revenue for the quarter was up 11.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.46 earnings per share. On average, equities research analysts predict that Stryker Co. will post 12.06 EPS for the current year.

Insider Activity

In other news, insider Viju Menon sold 600 shares of the stock in a transaction on Tuesday, August 27th. The stock was sold at an average price of $355.00, for a total value of $213,000.00. Following the completion of the sale, the insider now owns 9,069 shares in the company, valued at $3,219,495. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other Stryker news, insider Viju Menon sold 600 shares of the firm's stock in a transaction dated Tuesday, August 27th. The stock was sold at an average price of $355.00, for a total transaction of $213,000.00. Following the transaction, the insider now directly owns 9,069 shares in the company, valued at $3,219,495. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP M Kathryn Fink sold 2,121 shares of Stryker stock in a transaction on Friday, September 13th. The stock was sold at an average price of $370.00, for a total transaction of $784,770.00. Following the completion of the transaction, the vice president now owns 10,042 shares in the company, valued at $3,715,540. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 10,068 shares of company stock worth $3,693,972. Insiders own 5.50% of the company's stock.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the company. Royal Bank of Canada increased their price target on Stryker from $386.00 to $400.00 and gave the stock an "outperform" rating in a report on Wednesday, October 30th. Wells Fargo & Company boosted their price objective on shares of Stryker from $381.00 to $405.00 and gave the stock an "overweight" rating in a research note on Wednesday, October 30th. Evercore ISI boosted their price objective on shares of Stryker from $380.00 to $384.00 and gave the stock an "outperform" rating in a research note on Wednesday, October 30th. StockNews.com upgraded Stryker from a "hold" rating to a "buy" rating in a research note on Tuesday, October 1st. Finally, Piper Sandler reissued an "overweight" rating and issued a $420.00 target price (up from $380.00) on shares of Stryker in a research report on Wednesday, October 30th. Four analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. Based on data from MarketBeat, Stryker currently has an average rating of "Moderate Buy" and an average price target of $393.65.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.